Learn more about SAB Biotherapeutics’ unique immunotherapy platform and its pipeline of novel clinical and preclinical programs—click here to watch a replay of the company’s recent Virtual R&D Day

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases

Company Overview

We are a newly organized, blank check company formed as a Delaware corporation for the purpose of effecting an initial business combination with one or more target businesses. We have not selected any specific target business and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any target business regarding an initial business combination with our company. While we may pursue an acquisition opportunity in any industry or sector, we intend to capitalize on our management team’s differentiated ability to source, acquire and manage a business in the life sciences industry.

Stock Snapshot

Investor Contact Information

Company

Big Cypress Acquisition Corp.
300 W. 41st Street
Suite 202
Miami Beach, FL 33140
ir@bigcypressaccorp.com

Transfer Agent

Continental Stock Transfer & Trust
1 State Street
30th Floor
New York, NY 10004
T: 212-509-4000
cstmail@continentalstock.com
continentalstock.com